pathology
revealed
News & Articles
Reveal Biosciences Joins the CellCarta Family
CellCarta Strengthens its Histological Biomarker Franchise by Acquiring Artificial Intelligence-Based Quantitative Pathology Leader Reveal Biosciences MONTREAL, Canada, May 11th, 2021 / CNW – CellCarta, a global provider of precision medicine services, announced today the acquisition
Reveal Biosciences Creates A New Artificial Intelligence Approach to Spatial Genomics in Partnership with QuantumCyte
The partnership paves way for the integration of AI-driven spatial genomics with a unique cloud-based platform (SAN DIEGO, Jan. 19, 2021) — Reveal Biosciences, Inc., a leader in AI digital Pathology Intelligence™, announced today its
Reveal Biosciences’ AI-powered imageDx™ platform expedites pathology review of over 3,500 slides for COVID study
The universal demand to bring a COVID vaccine to market has expedited timelines in both preclinical and clinical research. While vaccine development efforts have been accelerated, traditional pathology evaluation struggles to change: Hematoxylin & Eosin-stained
Reveal Biosciences Announces the Launch of imageDx™ A Unique Cloud-based AI Pathology Platform
imageDx™ platform creates a new generation of Pathology Intelligence™ (SAN DIEGO, CA. Jan. 12, 2021) — Reveal Biosciences, Inc., an established AI data provider, has developed a powerful and dynamic SaaS pathology platform called imageDx™.
AI Powered Pathology and Spatial Genomics: a Precision Medicine Approach
Spatial genomics and digital pathology continue to evolve at a rapid pace, generating large amounts of data. There is a critical unmet need for advanced tools to expedite spatial data generation, visualization, and analysis to
Data Powered Histopathology for IBD Research
Millions of people worldwide suffer from inflammatory bowel disease (IBD). In 2015, 3 million adults in the U.S. were diagnosed with IBD, with 70,000 new cases reported. IBD consists of two major disorders: ulcerative colitis
Poster – Quantitative Histopathological Analysis of a Diet-Induced NASH Mouse Model Using Artificial Intelligence
In a unique collaboration between multiple companies, Reveal has applied deep learning-based models to validate a diet-induced mouse NASH model that can be utilized in directed research studies for therapeutic drug development. Along with the
Validation of a NASH Mouse Model – White Paper
Validation of an Off-the-Shelf, Diet-Induced NASH Mouse Model using Digital Whole Slide Scanning of Liver Tissue and Artificial Intelligence-Enabled, Quantitative Histopathological Analysis Download the PDF White Paper Summary: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic
COVID-19: New Histopathology Capabilities for Research
Collaboration within the scientific community is essential for rapid progress. Our highly skilled team is ready to accelerate your COVID-19 research. In this time of uncertainty one thing is clear – accurate data matters. Quantitative In
NASH: IHC Digital Assays for Immune Cell Quantification
Research into developing effective treatments for non-alcoholic steatohepatitis (NASH) is becoming more important as the incidence of NASH increases in the general population. Mouse and rat models are used in the development of NASH therapeutics
